# HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

> **NCT04684914** · PHASE2 · TERMINATED · sponsor: **Altimmune, Inc.** · enrollment: 87 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **BIOLOGICAL:** HepTcell
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04684914
- **Lead sponsor:** Altimmune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-26
- **Primary completion:** 2024-03-27
- **Final completion:** 2024-04-17
- **Target enrollment:** 87 (ACTUAL)
- **Why stopped:** Did not meet endpoints
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04684914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04684914, "HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04684914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*